GlassScriptPhysician profile
Ashley Oldroyd Radmall
NPI 1346824950
$8,023.64
in general payments reported to CMS, 2019-2025
27 companies · $2,904 in 2025
The $2,904 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $672 · 2023: $2,081 · 2024: $2,366 · 2025: $2,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,363 · Consulting Fee: $1,943 · Education: $45.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,362.82 |
| Consulting Fee | $1,942.86 |
| Education | $45.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,077.79 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $678.13 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $667.30 | 2022-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $646.16 | 2022-2025 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $586.51 | 2022-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $559.98 | 2022-2025 | |
| Amgen INC. | $457.92 | 2022-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $383.82 | 2022-2025 | Veltassa |
| Novo Nordisk INC | $259.74 | 2022-2025 | Rybelsus, Ozempic, Rivfloza |
| Fresenius USA Marketing, INC. | $241.79 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Glaxosmithkline, LLC. | $194.97 | 2022-2025 | Benlysta |
| Cormedix INC. | $164.91 | 2024-2025 | Defencath, Defencath |
| Mallinckrodt Hospital Products INC. | $153.79 | 2022-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.62 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $129.55 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $125.85 | 2023 | Krystexxa |
| Lilly USA, LLC | $122.20 | 2023-2024 | Jardiance |
| Baxter Healthcare | $99.23 | 2022-2024 | Renal - Pd, Renal - Chronic |
| Alexion Pharmaceuticals, INC. | $95.42 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $72.62 | 2023-2025 | |
| Rhythm Pharmaceuticals, INC. | $36.27 | 2023-2024 | Imcivree, Imcivree |
| Takeda Pharmaceuticals U.S.A., INC. | $32.23 | 2023 | Gattex |
| Hologic Sales and Service, LLC | $29.37 | 2024 | Myosure Tissue Removal Device |
| Scpharmaceuticals INC. | $18.40 | 2025 | |
| Merz North America, INC. | $14.31 | 2024 | |
| Aurinia Pharma U.S., INC. | $14.17 | 2023 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Radmall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.